Hematopoietic Malignancies

恶性血液病计划区由21名成员组成，横跨6个部门 加州大学洛杉矶分校。在过去的竞争周期中，该项目的调查人员撰写了372份出版物，其中104份 (28%)是方案间的，59(16%)是方案内的。120人(32%)处于高冲击状态 日记。本计划领域的18个成员使用了JCCC目前资助的共享资源中的7个。当前 该项目的同行评审资金总额为610万美元，其中130万美元来自NCI。 JCCC向恶性血液病项目提供了略高于260万美元的资金，以支持 其成员和活动。这些资金支持种子赠款、招聘和留用、薪金支助 为员工提供计划领导力和薪资支持。 项目区成员的兴趣包括确定HSC在 胚胎，早期干细胞和未成熟胚胎之间的谱系关系的描述，谱系特定 祖细胞，阐明调节血细胞的细胞内信号和转录途径 发育，以及衰老对血细胞产生的影响。这种力量在一定程度上是由于 新教师的招聘，Eli和Edyth Bright再生医学中心的创建，以及 加州大学洛杉矶分校(以下称为加州大学洛杉矶分校广泛干细胞中心)的干细胞研究，以及 加州再生医学研究所(CIRM)提供了相当多的机会。一个 下面将详细介绍的特别重要的发展是人类胚胎干细胞的使用 (HESC)建立造血细胞模型。 我们的淋巴瘤基础和临床计划通过招募两名初级医生而得到加强 内科医生/科学家到教员。在这方面，提高淋巴瘤疗效的新战略 疫苗接种将很快进入临床试验，而针对EBV阳性淋巴瘤的第一阶段试验将 正在进行中，已经招募了患者。因此，淋巴瘤主题的进一步发展是一个 第二个主要计划目标，几个计划区域成员是一个跨机构的成员 已经提交给国家癌症研究所的淋巴瘤赠款。

The Hematopoietic Malignancies Program Area is composed of 21 members, spanning 6 Departments within UCLA. In the past competing cycle, investigators from this Program authored 372 publications, of which 104 (28%) were inter-programmatic and 59 (16%) intra-programmatic. 120 (32%) were placed in high-impact journals. 18 members of this Program Area used 7 of the currently funded JCCC Shared Resources. Current peer-reviewed funding for this program totals $6.1M of which $1.3M is awarded from NCI. The JCCC has provided the Hematopoeitic Malignancies Program with slightly more than $2.6M in support of its members and activities. These funds supported seed grants, recruitment and retention, salary support for program leadership and salary support for staff. The interests of program area members include the identification of the sites in which HSC emerge in the embryo, the delineation of lineage relationships between early stem and immature, lineage specified progenitor cells, the elucidation of intracellular signaling and transcriptional pathways that regulate blood cell development, and the effects of aging on blood cell production. This strength has in part evolved as a result of the recruitment of new faculty, the creation of the Eli and Edyth Broad Center of Regenerative Medicine and Stem Cell Research at UCLA (hereafter referred to as the UCLA Broad Stem Cell Center), and the considerable opportunities made possible by the California Institute for Regenerative Medicine (CIRM). A particularly significant development that will be detailed below is the use of human embryonic stem cells (hESC) to model hematopoiesis. Our basic and clinical program in lymphoma has been strengthened by the recruitment of two junior physician/scientists to the faculty. In this regard, new strategies to improve the efficacy of lymphoma vaccination will soon be introduced into clinical trials while a Phase I trial to target EBV-positive lymphomas is underway and has already enrolled patients. Thus, the further development of the lymphoma theme is a second major program goal, and several program area members are members of an inter-institutional lymphoma grant that has been submitted to the National Cancer Institute.